A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Adenocarcinoma; Breast cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 05 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 05 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology